In the fluvastatin XL group , the proportion of patients with moderate cardiovascular ( CV ) risk and high CV risk achieving their LDL-C treatment goals at endpoint was @ % and @ % respectively , while the proportion was @ % and @ % respectively in the fluvastatin IR group .